Magle Chemoswed Holding AB (publ)

MAGLE.ST

Biotechnology · Healthcare

Exchange

Stockholm Stock Exchange

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Weak

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Magle Chemoswed is a Swedish healthcare company that makes specialty pharmaceutical products and provides contract development and manufacturing services. Its main products include excipients — ingredients used inside medicines to help them work properly — along with drug formulation services sold to pharmaceutical companies and research institutions. The company operates in two main areas: its own branded pharmaceutical products and fee-based services for other drugmakers.

The company earns money through product sales and service contracts with pharmaceutical clients, primarily in Europe. It is a small-cap company with a market capitalization around $100 million, and its edge comes from niche technical expertise in pharmaceutical formulation and a long operating history in Scandinavia. However, the deeply negative operating margin shows the company is currently spending far more than it earns, which is a significant financial risk. The key challenge ahead is scaling revenue fast enough to cover its cost base and reach profitability before it needs to raise additional capital.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+39.2% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+39.3% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

45.8%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~0 months

kr 2M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Revenue accelerating

Magle Chemoswed Holding AB (publ) grew revenue 39% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-19.4%

Thin — -19.4% gross margin

Profit after running costs

Operating Margin

-19.4%

Losing money on operations — -19.4%

Return on the money invested

ROCE

-23.8%

Weak — -23.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+1.8%

Nearly flat sales (+1.8% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-55.0%

Burning cash (-55.0%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

1.22

Elevated debt (1.22)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial